Practice Points
Introduction 54
Fatigue is a common symptom of Multiple Sclerosis (MS) reported in over 70% of the 55 population. 1-3 MS-related fatigue is often perceived as the most debilitating symptom, which 56 significantly impacts upon activities of daily living, social participation and quality of life, 4-5 57 and is associated with changes to employment. 6 Fatigue is a highly complex and 58 multifactorial symptom that may be defined as "a subjective lack of physical and/or mental 59 energy that is perceived by the individual or caregiver to interfere with usual and desired 60 activities". 7 Subjectively, this may be described as exhaustion, a lack of energy, or 61 overwhelming tiredness which is pervasive and can occur at rest. 8 62
Although fatigue can be experienced throughout the course of MS, it has a higher 63 prevalence amongst people with progressive forms of the disease. 1, [9] [10] Web of Science Core Collections. Search strategies included a combination of keywords and 96 subject headings related to multiple sclerosis, exercise, behavioural therapy, rehabilitation 97 and fatigue, and were adapted for use in each different database ( Supplementary table 1) . 98
Reference lists of relevant review articles were also hand searched to identify any additional 99 articles. After each database was searched, results were exported to Covidence systematic 100 review software (2017, Veritas Health Innovation, Melbourne, Australia) and duplicates were 101 removed prior to screening. The primary reviewer (SR) initially screened all articles by title 102 and then by abstract against the inclusion and exclusion criteria. Subsequently, two reviewers 103 (SR and LP) independently screened full texts of the remaining articles for eligibility. 104
Disagreements were resolved through consensus in consultation with a third reviewer (FM) if 105 required. 106 107
Inclusion and exclusion criteria 108
To be included in this review studies had to have: (i) recruited adults with a definite 109 diagnosis of MS and a progressive form of the disease (secondary or primary progressive); 110 (ii) evaluated non-pharmacological interventions in accordance with the definitions provided 111
in Table 1 ; (iii) used a self -reported measure of fatigue impact or severity as either a primary 112 or secondary outcome (including sub-scales of questionnaires); (iv) used a randomised 113 controlled trial or quasi-experimental design; (v) been published in English. Studies that 114 included a combination of types of MS were only included when specific results for those 115 with progressive MS could be identified. Non-human studies, pharmacological studies, and 116 conference proceedings and abstracts were excluded from this review. 117 
Quality assessment
Quality of evidence was assessed using the Downs and Black checklist -a 32-point 127 scale developed for quality assessment of both randomised controlled trials (RCTs) and non-128
RCTs. 24-25 An initial quality assessment was conducted where each of the three reviewers 129 independently scored an article to ensure consistency in assessment between reviewers. 130
Following this quality assessment, question 27 of the checklist was modified such that an 131 article was assigned 1 point for including a sample size calculation and zero if the article did 132 not, resulting in a total possible score of 28. This modification was implemented in keeping 133 with two systematic reviews of exercise interventions in MS. [26] [27] Quality assessment was 134 completed independently by two reviewers. When discrepancy arose, agreement was reached 135 through consensus in consultation with a third reviewer. 136 137
Data synthesis

138
Due to the inclusion of quasi-experimental studies and heterogeneity in study design, 139 it was not feasible to conduct a meta-analysis; therefore, results were generated through 140 narrative synthesis. Preliminary synthesis involved a descriptive summary of key information 141 extracted from all articles. Individual study estimates of treatment effects were presented 142 under each mode of intervention and explored within and between studies considering 143 moderator variables to explain differences in results. Where available, results for the relevant 144 fatigue outcome measures were compared to minimal clinically important difference 145 (MCID). 146
Results
148
Results of the search 149
Through searching the selected electronic databases, 560 articles were identified, and 150 an additional 4 articles were added from references lists of relevant studies (Figure 1 ). After 151 removing duplicates, 463 articles remained for title and abstract screening of which 308 were 152 excluded by title and 97 by abstract. The remaining 58 articles were included for full-text 153 screening. After screening full-texts, 45 articles were excluded as the results of those with 154 progressive MS were not identifiable in 41 studies (either MS type was not reported, or 155 results for those with progressive MS were not presented separately), 3 studies did not 156 include participants with progressive MS, and 1 study did not include a fatigue outcome 157 measure. Two articles described the same study but reported different outcome measures; 29-30 158 therefore, 13 articles from 12 studies were included (Table 2) There were seven self-reported outcome measures used across the included articles to 195 measure the impact and/or severity of fatigue -the most commonly used were the FSS 196 (n=4), 32, 38-39, 41 and the Modified Fatigue Impact Scale (MFIS) (n=4). [34] [35] [36] 40 In addition, 197 studies also used the Fatigue Impact Scale (FIS), 31 were performed at moderate intensity, and were progressed through increasing the duration of 216 training; however, the study by Skjerbaek et al implemented a high intensity interval training 217 protocol involving three minute intervals working at a heart rate corresponding to 65-75% 218 VO 2peak . 37 In addition to aerobic exercise, the combined exercise intervention described by 219
Roehrs and Karst incorporated elements of upper and lower limb resistance exercises, and 220 was delivered in a pool by physical therapy students. The mechanisms through which exercise may attenuate fatigue symptoms are 335 unknown. It is hypothesised that exercise may have a neuroprotective and neuroregenerative 336 benefit through increasing neural growth factors which modulate structural and functional 337 CNS changes associated with primary MS-related fatigue. 13 In addition, exercise training can 338 influence secondary fatigue mechanisms caused by deconditioning, sleep disorders, and 339 depression through increasing aerobic capacity, improving sleep quality, and managing 340 depression. 13 Immunological biomarkers interferon-γ, tumour necrosis factor α, and 341
interleukin-1 have also been associated with fatigue in MS, 44 but may have limited relevance 342 to those with progressive MS due to the absence of a marked inflammatory response. 45 343
Of the aerobic exercise interventions included, three were performed at moderate 344 intensity for durations of between 30-45 minutes, 2-3 times per week. [35] [36] 40 While this dose 345 of exercise is recommended for people with mild-moderate MS, 46 there was no evidence of a 346 dose-response relationship to suggest that this prescription is most effective in managing 347 fatigue -particularly in progressive MS populations. Indeed, one trial investigated shorter 348 duration, high-intensity aerobic exercise, 37 which may hold potential in fatigue management 349 through inducing greater improvements in aerobic capacity over a shorter time. 47 was designed to manage distress not fatigue. 39 Therefore, despite the association between 378 mood disorders and fatigue, 9, [49] [50] [51] the applicability of these findings to fatigue management is 379 limited. In addition, the mindfulness sessions were delivered via video conference which, 380 while accommodating those with severe mobility disabilities, may limit the social benefits 381 reported during group based interventions delivered face-to-face. 33 Notes: 2, criterion fully met (item 5); 1, criterion met or partially met (item 5); 0, criterion not met *Abbreviated Downs and Black checklist item description: 1, hypothesis/aims/objectives reported; 2, main outcome measures reported; 3, participant characteristics reported; 4, intervention details reported; 5, principal confounders reported; 6, main findings reported; 7, variability in main outcomes reported; 8, adverse events reported; 9, loss to follow-up reported; 10, probability values reported; 11, source population representative of entire population; 12, study population representative of source population; 13, study setting representative of usual care; 14, participants blinded to intervention; 15, outcome assessors blinded; 16, no retrospective sub-group analysis; 17, analysis adjusts for different lengths of follow-up of participants; 18, statistical tests are appropriate; 19, reliable compliance with intervention; 20, outcome measures are valid and reliable; 21, recruitment of study groups from same population; 22, recruitment of participants over
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